Hercules Technology expects gain from Sirtris acquisition

Recs

0

Investment firm Hercules Technology Growth Capital Inc. said Thursday that it expects to realize a gain as a result of GlaxoSmithKline PLC's acquisition of Sirtris Pharmaceuticals Inc.

Hercules said it plans to provide details when it releases its earnings on May 8.

U.K.-based GlaxoSmithKline said Tuesday it will pay about $720 million, or $22.50 per share through a cash tender offer, for Cambridge, Mass.-based Sirtris.

The deal has been approved by the boards of both companies and is subject to customary closing conditions. The companies expect the tender offer to begin in early May and close in the second quarter.

Hercules said it provided Sirtris with $15 million debt financing in April 2006. Sirtris later completed an initial public offering of 6.9 million shares of common stock in May 2007, raising $62.4 million, Hercules said.

Hercules shares rose 11 cents to close at $10.50.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 629633, ~/articles/articlehandler.aspx, 12/2/2008 5:57:19 AM,

Sign up for FREE Motley Fool site access to keep reading:

“Hercules Technology expects gain from Sirtris acquisition”

Signing up allows you to comment on articles and on the discussion boards.

It's completely FREE and will take only 10 seconds.

Privacy / Legal Information

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement

.

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

What Fools Are Saying

Most Recent

Most Recommended

Market Summary

S&P 500816.21 -8.93%
DJIA8,149.09 -7.70%
NASD1,398.07 -8.95%
Updated: 4:04:56 PM
Sponsored by:

Related Tickers

GlaxoSmithKline plc (ADR)

CAPS Rating 4/5 Stars

$32.02

-2.42 (-7.03%)

Outperform938

Underperform61

Rate This Stock